Induction of Epstein-Barr virus lytic cycle by tumor-promoting and non-tumor-promoting phorbol esters requires active protein kinase C
- PMID: 1658377
- PMCID: PMC250778
- DOI: 10.1128/JVI.65.12.6838-6844.1991
Induction of Epstein-Barr virus lytic cycle by tumor-promoting and non-tumor-promoting phorbol esters requires active protein kinase C
Abstract
Exposure to the tiglian 12-O-tetradecanoylphorbol-13-acetate (TPA) represents one of the most efficient and widely used protocols for inducing Epstein-Barr virus (EBV)-infected cells from latent into lytic cycle. Since TPA is both a potent tumor promoter and a potent activator of the cellular protein kinase C (PKC), we sought to determine whether either of these activities was closely linked to EBV lytic cycle induction. A panel of TPA structural analogs, encompassing tiglians with different spectra of biological activities, was assayed on a number of EBV-positive B-lymphoid cell lines. Lytic cycle induction correlated with the capacity to activate PKC, not with tumor promoter status; some nonpromoting tiglians were as efficient as TPA in inducing lytic cycle antigen expression. We then sought more direct evidence for an involvement of PKC in the induction process. In initial experiments, 1-(5-isoquinolinyl sulphonyl)-2-methylpiperazine (H-7), the best available pharmacological inhibitor of PKC, completely blocked the induction of the lytic cycle by TPA and its active analogs. This is consistent with, but does not prove, a requirement for active PKC in the induction process, since H-7 targets PKC preferentially but also has some effects on other kinases. We therefore turned to the synthetic pseudosubstrate peptide PKC(19-36) as a means of specific PKC inhibition and to the closely related but inactive peptide PKC(19-Ser-25-36) as a control. Using the technique of scrape loading to deliver the peptides into cells of an adherent EBV-positive target line, we found that the pseudosubstrate peptide PKC(19-36) completely and specifically blocked tiglian-induced entry of the cells into the lytic cycle. The evidence both from TPA analogs and from enzyme inhibition studies therefore indicates that the pathway linking TPA treatment to lytic cycle induction involves active PKC. Interestingly, inhibition of PKC had no effect upon the spontaneous entry into lytic cycle which occurs in naturally productive cell lines, suggesting that spontaneous entry is signalled by another route.
Similar articles
-
Protein kinase C-independent activation of the Epstein-Barr virus lytic cycle.J Virol. 2002 Jun;76(11):5612-26. doi: 10.1128/jvi.76.11.5612-5626.2002. J Virol. 2002. PMID: 11991990 Free PMC article.
-
Effect of protein kinase C inhibitors with different action mechanisms on Epstein-Barr virus replication.Intervirology. 1992;33(4):217-24. doi: 10.1159/000150254. Intervirology. 1992. PMID: 1326499
-
De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi's sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists.J Virol. 2007 Sep;81(17):9279-91. doi: 10.1128/JVI.00982-07. Epub 2007 Jun 27. J Virol. 2007. PMID: 17596302 Free PMC article.
-
Epstein-Barr virus and tumor promoters.Princess Takamatsu Symp. 1983;14:139-45. Princess Takamatsu Symp. 1983. PMID: 6097578 Review.
-
Protein kinase C pharmacology: refining the toolbox.Biochem J. 2013 Jun 1;452(2):195-209. doi: 10.1042/BJ20130220. Biochem J. 2013. PMID: 23662807 Free PMC article. Review.
Cited by
-
Cellular immediate-early gene expression occurs kinetically upstream of Epstein-Barr virus bzlf1 and brlf1 following cross-linking of the B cell antigen receptor in the Akata Burkitt lymphoma cell line.J Virol. 2010 Dec;84(23):12405-18. doi: 10.1128/JVI.01415-10. Epub 2010 Sep 22. J Virol. 2010. PMID: 20861250 Free PMC article.
-
The mTOR inhibitor manassantin B reveals a crucial role of mTORC2 signaling in Epstein-Barr virus reactivation.J Biol Chem. 2020 May 22;295(21):7431-7441. doi: 10.1074/jbc.RA120.012645. Epub 2020 Apr 20. J Biol Chem. 2020. PMID: 32312752 Free PMC article.
-
MCAF1 and Rta-activated BZLF1 transcription in Epstein-Barr virus.PLoS One. 2014 Mar 5;9(3):e90698. doi: 10.1371/journal.pone.0090698. eCollection 2014. PLoS One. 2014. PMID: 24598729 Free PMC article.
-
Synthesis of infectious human papillomavirus type 18 in differentiating epithelium transfected with viral DNA.J Virol. 1997 Oct;71(10):7381-6. doi: 10.1128/JVI.71.10.7381-7386.1997. J Virol. 1997. PMID: 9311816 Free PMC article.
-
Targeting Epstein-Barr Virus in Nasopharyngeal Carcinoma.Front Oncol. 2020 May 14;10:600. doi: 10.3389/fonc.2020.00600. eCollection 2020. Front Oncol. 2020. PMID: 32528868 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources